Search over 5957 companies active in the biomedical industry with 367713 press releases and 50000+ clinical trials.
 Subscribe Today

Selecting a business or clinical category below will actively search the DMS NewsAnalyzer database for current press releases on the specific topic. For advanced search and reporting options, please visit the Products & Services page.

Categories Date Company Title (click for full text)
2008-05-15 Touch Bionics Touch Bionics Acquires LIVINGSKIN
Newburgh, NY, USA and Livingston, Scotland – May 15, 2008 – Touch Bionics, developer of the i-LIMB Hand, the world’s first commercially available, multi-articulating bionic hand, today announced that it has acquired the complete operations of LIVINGSKIN, the developer of the unique and lifelike prosthetic skin that Touch Bionics supplies with its ground-breaking product. The acquisition will allow Touch Bionics to fulfil growing customer demand from across the world, while applying its commercial and technical expertise into new cosmesis solutions for multi-articulating hands and digits.
2008-05-15 Theratechnologies Theratechnologies explores tesamorelin in growth hormone deficient abdominal obesity
Montreal, May 15, 2008 - Theratechnologies (TSX: TH) announced today a strategic agreement with both the Massachusetts General Hospital ("MGH") and Dr. Steven Grinspoon to explore the use of tesamorelin in relative growth hormone deficient abdominally obese (GHDAO) subjects. MGH, under the direction of Dr. Grinspoon, will sponsor and conduct a clinical trial with tesamorelin in subjects that have excess visceral adipose tissue (VAT) with a moderate growth hormone deficiency and who are abdominally obese. The combination of these factors is now being recognized as an important contributor to increased risk of cardiovascular disease. Therefore, one of the reasonable approaches to lower the cardiovascular risk in these subjects is to decrease VAT levels with tesamorelin to replenish growth hormone secretion, and to measure certain key markers of cardiovascular risk. Theratechnologies has demonstrated in various Phase 2 and 3 clinical trials that tesamorelin significantly and specifically reduces VAT in certain patient populations.
2008-05-14 Dynatronics Dynatronics’ Acquisitions Boost Sales 80 Percent in Third Quarter
Salt Lake City, Utah (May 14, 2008) – Dynatronics Corporation (NASDAQ: DYNT) today announced results for its third fiscal quarter ended March 31, 2008. Sales for the quarter increased 80 percent to $7,781,871, compared to $4,330,440 in the prior year period. For the nine months ended March 31, 2008, sales increased 90 percent to $24,534,934, compared to $12,897,679 in the prior year period. The increase in sales was due primarily to the acquisition of six of the company’s top independent distributors on June 30, 2007, and July 2, 2007. Dynatronics now has 40 direct sales reps covering 30 states across the country in addition to its well-established domestic and international dealer network.
2008-05-14 McKesson McKesson Acquisition of Vivalog to Deliver Case Sharing and Clinical Conferencing
May 14, 2008 -- ATLANTA-- McKesson today announced it has acquired Vivalog LLC, a leading provider of Web-based solutions, including its MyPACS.net medical imaging reference site, that enable radiologists, cardiologists, and other imaging specialists to efficiently organize and share image and reference case information needed during daily practice. This portfolio extends current hospital imaging and information management systems with reference case management and clinical conferencing capabilities that result in rich, multimedia knowledge repositories to assist in diagnostics as well as research and training.
2008-05-14 Newron Pharmaceuticals Newron closes acquisition of Hunter-Fleming
Milan, Italy – May 14, 2008 - Newron Pharmaceuticals S.p.A. (“Newron”, SWX: NWRN), a research and development company focused on novel CNS and pain therapies, today announced that it has completed the acquisition of Hunter-Fleming Ltd., a private UK bio-pharmaceutical company developing new medicines to treat neurodegenerative and inflammatory disorders. As announced earlier, shareholders of Hunter-Fleming now hold 3.1 % in Newron.
Results 1-5 of 107
Benefits of Subscription
  Unlimited number of in-depth searches
  Download formatted reports of your results
  Create favorites with optional email notification
  World wide company coverage
  Multiple database and user discounts available


About DMS Data Systems:
DMS DATA is an information company focused on providing data resources to companies and organizations around the globe that work in the biomedical industry and related fields. DMS products and services include the development of online subscription databases, website content monitoring, and data feeds.
Contact Us:
DMS Data Systems LLC
258 Harvard Street
PMB 370
Brookline, MA 02446
USA
Tel: +1-617-517-3178
info@dmsdatasystems.com
© 2007 DMS Data
All Rights Reserved